Quarterly ResultJun 2, 2026, 04:23 PM
PetMed Express Q4 Sales Down 15.6%; Full Year Loss Widens to $57.3M
AI Summary
PetMed Express announced its fourth quarter and fiscal year 2026 financial results, reporting a significant year-over-year decline in net sales for both periods, primarily due to a drop in prescription medication sales. While the company narrowed its net loss in the fourth quarter, the full fiscal year saw a substantial increase in net loss, impacted by goodwill impairment charges and increased stock-based compensation. Despite receiving unsolicited acquisition proposals, the company's Board decided not to proceed, opting to remain an independent entity.
Key Highlights
- PetMed Express reported Q4 FY2026 net sales of $42.8 million, a 15.6% decrease year-over-year.
- Q4 FY2026 net loss was $4.1 million, or $(0.19) per diluted share, an improvement from a $11.6 million net loss in the prior year.
- Full year FY2026 net sales decreased 21.1% to $179.0 million.
- Full year FY2026 net loss widened to $57.3 million, or $(2.74) per diluted share, compared to a $6.3 million net loss in FY2025.
- Adjusted EBITDA for Q4 FY2026 was $(2.8) million, compared to $(1.9) million in the prior year period.
- Adjusted EBITDA for full year FY2026 was $(15.4) million, compared to $0.7 million in the prior year.
- The company received unsolicited acquisition proposals in December 2025 ranging from $4.00 to $4.25 per share but decided not to proceed with them.
Price Impact
More from PETS